新經典(603096.SH):2022年內上市新書205種
格隆匯5月17日丨有投資者向新經典(603096.SH)提問:公司目前新書出品的數量是多少?未來是否會在趨勢上呈增長態勢?今年有什麼重點新書?
新經典回覆:公司2022年內上市新書205種,其中大眾書113種,童書92種。未來公司不會大規模增加新品數量,仍將堅守“有益、有趣、經得起時間”的選品策劃理念,打造更為優質的內容產品,建設多媒體內容營銷與傳播體系,促進銷售轉化,實現單品效益的提升,儘可能延長產品生命週期。
2023年公司的重點新書包括東野圭吾的《白鳥與蝙蝠》、王朔的《紀年·竹書》、諾獎作家門羅和著名學者許倬雲的新作等,童書方面包括《內褲超人》、吉竹伸介等新作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.